28
Technology2h 12m ago

Ractigen Therapeutics announced a publication in Nature Medicine detailing preclinical efficacy and positive first-in-human clinical data for its therapy RAG-17 in SOD1-ALS.

Not specified

Who
Ractigen Therapeutics
What
Ractigen Therapeutics announced a publication in Nature Medicine detailing preclinical efficacy and positive first-in-human clinical data for its therapy RAG-17 in SOD1-ALS.
When
Wed, 15 Jul 2026 13:08:28 GMT · 2h 12m ago
Where
Not specified ·
Why
The publication highlights RAG-17's translation from preclinical research to early human trials, validating the SCAD™ delivery platform for CNS-targeted RNAi therapies.
The Frontline Impact

How this affects you

The data supports the potential of RAG-17 as a treatment for SOD1-ALS and validates the SCAD™ delivery platform for future central nervous system therapies.

Story chain

1 event in this thread
No related history yet - this is the origin event.

Verified Sources & Citations

Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.